Povorcitinib Trial for Hidradenitis Suppurativa
Phase 2
40
about 2.3 years
12–17
23 sites in AL, AZ, CT +14
What this study is about
Researchers are testing povorcitinib, a medication, in adolescents with moderate to severe hidradenitis suppurativa. The trial will last 832 days and evaluate the drug's safety and effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Povorcitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor
Primary: Apparent clearance, Proportion of participants with Treatment-Emergent Adverse Events (TEAEs), Terminal half-life
Secondary: Change from baseline in Children's Dermatology Life Quality Index (CDLQI) score at each visit, Mean change from baseline in abscess count at each visit, Mean change from baseline in draining tunnel count at each visit, Mean change from baseline in inflammatory nodule count at each visit, Mean percentage change from baseline in abscess count at each visit, Mean percentage change from baseline in draining tunnel count at each visit, Mean percentage change from baseline in inflammatory nodule count at each visit, Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)30 among participants with baseline Skin Pain NRS score ≥ 3